menu
Short Bowel Syndrome Market 2027: Global Demand, Key Players, Overview, Supply and Consumption Analysis
Short Bowel Syndrome Market 2027: Global Demand, Key Players, Overview, Supply and Consumption Analysis
“Coherent Market Insights “SHORT BOWEL SYNDROME MARKET – GLOBAL TRENDS, ESTIMATES AND FORECASTS, 2020-2027?

Shortbowel syndrome (SBS) is a malabsorption syndrome caused by lack of a functionalsmall intestine. The primary symptoms of SBS are diarrhea followed bydehydration, weight loss, and malnutrition. If SBS is left untreated it canlead to kidney stones. The primary reasons behind short bowel syndrome inchildren are damaged intestinal tissue, blockage or obstruction in intestine,gastroschisis, and rotation of the midgut also known as malrotation and ingrown-ups. Short bowel syndrome is detected in Crohn’s disease, radiationenteritis, and mesenteric ischemia. This syndrome usually occurs in cases dueto surgical elimination of major portion of small intestine

MarketDynamics- Drivers

Increasing incidence of shortbowel syndrome worldwide is expected to drive growth of the global short bowelsyndrome market during the forecast period. Accordingto Crohn’s & Colitis Foundation of America, in 2010 there were10,000–20,000 people in the reported cases of short bowel syndrome, out ofwhich 25% people suffered some or the other complication within two years ofcontracting the condition. The rate of absorption decreases and due of lack ofsufficient nutrients to the body, many children die due to malnutrition.According to Sancilio and Company, Inc., most cases of short bowel syndrome aredue to birth in congenital anomaly, in which there occurs a rotation of midgutand the child die before the age of 6 years. According to Nutrinia Ltd, theexisting approach to treat infants suffering from short bowel syndrome includesproper nutritional, pharmacologic, and surgical interventions. The primary aimis to promote enteral nutrition, while curtailing the difficulties ofparenteral nutrition therapy.

* The sample copy includes: ReportSummary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.

Request asample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/169

Mostof the patients are given long-term parenteral treatment, which affects thepatient and significantly increases the chances of liver disease, infections,and other complications. Babies who have substantial short bowel syndromefrequently struggle from intestinal failure-associated liver disease,bloodstream infections, and bacterial overgrowth. Furthermore, parenteralnutrition leads to a substantial economic burden on the general population andthe healthcare system, with overall annual costs ranging from an estimated US$180,000 to US$ 570,000 and more.

GLP-2drug class dominates the leading markets in North America and Europe

Theglobal short bowel syndrome market is segmented on the basis of drug class andgeography. On the basis of drug class, the market is divided into GLP-2, growthhormone, glutamine and others.

RegionalInsights

Increasingprescription of Gattex Therapy for Short Bowel Syndrome in North Americacreates a highly lucrative prospect for growth

Regionalsegmentation of the short bowel syndrome market by Coherent Market Insightscomprises North America, Europe, Asia Pacific, Latin America, Middle East, andAfrica. Among regions, North America accounts for the largest share in globalshort bowel syndrome market, owing to presence of major players and earlyadoption of advanced medical technologies in countries such as the U.S. andCanada. According to National Institute of Diabetes and Digestive and KidneyDisease, in 2008, there were more than 2,000 intestinal transplantationsperformed in the U.S., out of which 75% population was of the age group of18-20 years. These numbers are expected to increase year on year, which wouldinadvertently fuel growth of the short bowel syndrome market.

BrowseResearch Report: https://www.coherentmarketinsights.com/ongoing-insight/short-bowel-syndrome-market-169

CompetitiveLandscape

Keyplayers operating the short bowel syndrome market include Ardelyx, Inc., EmmausLife Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, NAIA Pharmaceuticals,Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, andZealand Pharma A/S.

Keyplayers in the global short bowel syndrome market are focused on various growthopportunities such as product launches and approvals, in order to gain competitiveedge in the market. For instance, Nutrinia Ltd. plans to begin a criticalclinical trial on a drug for short bowel syndrome, which will aid thousands ofpatients globally by reducing their dependence on parenteral nutrition is themajor cause of liver infection.

Buy-Nowthis research report: https://www.coherentmarketinsights.com/insight/buy-now/169

AboutCoherent Market Insights:            

CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.

ContactUs:

mailto:sales@coherentmarketinsights.com

U.S.Office:

Name:  Mr. Shah

CoherentMarket Insights 1001 4th Ave,

# 3200Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737